ADCY7 (adenylate cyclase 7) is a transmembrane enzyme that catalyzes the formation of cyclic AMP (cAMP) and cyclic di-AMP (c-di-AMP) downstream of G protein-coupled receptor signaling 12. It mediates signaling cascades activated by thrombin, sphingosine 1-phosphate, dopamine, and anaphylatoxin C5a through synergistic action with G proteins GNAS and GNA13 123. Beyond canonical cAMP signaling, ADCY7 plays a critical immunological role by catalyzing c-di-AMP production following TLR9 activation, which directly activates NLRP3 to promote inflammasome assembly 4. Notably, ADCY7 undergoes nuclear translocation via caveolae-mediated endocytosis and functions as a transcription cofactor of CEBPA to induce CCL5 transcription, increasing CD8+ T cell infiltration in hepatocellular carcinoma 5. Disease relevance is substantial: ADCY7 loss-of-function mutations cause congenital hyperinsulinism by activating glucose-stimulated insulin secretion 6, while elevated ADCY7 expression correlates with poor survival in breast cancer, lung squamous cell carcinoma, and AML 78. ADCY7 also regulates vascular smooth muscle cell apoptosis in abdominal aortic aneurysm formation 9. These findings establish ADCY7 as a multifunctional immunomodulator with both pro-inflammatory and anti-tumor potential, suggesting therapeutic targeting in cancer and inflammatory diseases.